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ABSTRACT Neuroimmunomodulation has experi-
enced an explosive growth not only in basic research,
but expanding to the point that prospective clinical
research could be now a reality. A crucial factor for the
functioning of this intimate bidirectional network was
the demonstration that the immune and neuroendo-
crine systems speak a mutual biochemical language.
This implies 1) production of neuroendocrine hor-
mones and neuropeptides by immune cells and of
cytokines by neuroendocrine cells; 2) evidence for
shared receptors on cells of the immune and neuroen-
docrine systems; 3) effect of neuroendocrine media-
tors on immune functions; and 4) effect of cytokines on
the neuroendocrine system. This reduces traditional
differences between neurotransmitters, hormones, and
immune mediators and raises the following question:
what can we now regard as immune or neuroendocrine?
Vasoactive intestinal peptide (VIP) is one example of
this paradigm. VIP has traditionally been classiﬁed as a
neuropeptide/neurotransmitter based in its capacity to
mediate and regulate neuronal functions. Recent work
has demonstrated that VIP is produced by T cells,
especially Th2 cells, and that through speciﬁc receptors
it exerts immunological functions typically ascribed to
Th2 cytokines in nervous and immune systems. Here,
we postulate that instead of a neuropeptide, VIP could
be fully considered a type 2 cytokine with a key role in
neuroimmunology.—Pozo, D., Delgado, M. The many
faces of VIP in neuroimmunology: a cytokine rather a
neuropeptide? FASEB J. 18, 1325–1334 (2004)
Key Words: immune response  autoimmunity  Th cells  va-
soactive intestinal peptide
For many years immunologists have considered an
immune response to be a direct consequence of, and
solely determined by, antigenic stimulation of an au-
tonomous immune system, clearly pointing out the key
molecular questions for experimental investigation.
However, over the past two decades, we have come to
realize that the immune system is regulated by the
central nervous system (CNS) either directly or by way
of the neuroendocrine axis (i.e., the hypothalamic-
pituitary-adrenal system, HPA axis) or the autonomic
nervous system. The importance of these interactions is
underscored by a demonstration that immune and
nervous interactions, including neuropeptides, cyto-
kines, and speciﬁc immunomodulatory enzymes, have
been well conserved during the course of evolution.
Neuroimmunology is now sufﬁciently mature to begin
to consider organization, workings, behavior, and ap-
plications. A crucial factor for this intimate bidirec-
tional network to function was a demonstration that the
immune and neuroendocrine systems speak a mutual
biochemical language (Fig. 1). This reduces traditional
differences between neurotransmitters, hormones, and
immune mediators and raises the question of what can
actually be considered as immune or neuroendocrine?
More important, the ﬁnal outcome will most likely lead
to new unifying ideas and paradigms. The present
developmental stage in neuroimmunology in general,
and in VIP research in particular, can be characterized
as a transition from analysis (the reduction of observa-
tions to key molecules) to synthesis (an integration of
the parts into a whole). The difﬁculty in answering this
question starts when we try to deﬁne the terms neu-
ropeptide and cytokine exactly. De Wied and col-
leagues coined the term neuropeptide in 1974 by
deﬁning it as endogenous substances synthesized by
nerve cells and involved in nervous system functions
(1). However, whereas Kastin and Strand (2, 3) deﬁne
a neuropeptide as any peptide (independent of its cell
source) that has an action on the nervous system,
Iversen deﬁnes it as any peptide secreted from a
neuron (4). Although de Wied’s deﬁnition appears to
correspond to that accepted by most neuroscientists,
the discrepancy is served.
Cytokines, on the other hand, are deﬁned as small
regulator proteins that are expressed in and secreted
from immune cells and control survival, growth, differ-
entiation as well as effector functions of their target
cells. Originally identiﬁed as being important in inﬂam-
matory processes, the development and maintenance
of immune response, and for hematopoiesis, it is now
becoming evident that cytokines are involved at least to
some extent in most, if not in all, physiological pro-
cesses. Progress with the identiﬁcation of new cytokine
molecules is especially fast moving and new molecules
are discovered with alarming frequency. Although cy-
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tokines were considered to be a “family,” this is a
functional rather than a structural concept, as these
proteins are not all chemically related. Cytokines en-
compass those families of regulators variously known as
growth factors, colony-stimulating factors, interleukins,
lymphokines, monokines, and interferons.
The confusing nomenclature of cytokines has arisen
as several different streams of investigation led to the
discovery of different cytokines and, for example, mol-
ecules initially considered growth factors were later
reclassiﬁed as cytokines. Conversely, interleukins were
deﬁned in 1981 as molecules made by leukocytes that
Figure 1. The bidirectional interactions between the neuroendocrine and immune systems are mediated by anatomical
connections and mediators released and recognized by both systems, implying 1) neuroendocrine hormones and neuropeptides
produced by immune cells and cytokines by neuroendocrine cells; 2) common receptors expressed on cells of the immune and
neuroendocrine systems; 3) effects of neuroendocrine mediators on immune functions; and 4) effects of cytokines on the
neuroendocrine system.
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acted on leukocytes. Subsequent research has revealed
that some of these molecules are also made by and act
on nonleukocytes, and the nomenclature has stuck.
Despite overwhelming evidence for key immunomodu-
latory roles, the classical endocrine hormones have not
always enjoyed a good press, and modern textbooks of
immunology give scant attention to these compounds,
mainly because their general properties are different
from those of cytokines (Table 1). Nevertheless, there
are no sharp boundaries that distinguish cytokines
from other regulatory proteins. Some neuropeptides
are between these boundaries.
In this sense, VIP is a paradigmatic polypeptide that
has evolved from little more than a mere neuropep-
tide/hormone to a novel agent for modifying immune
function and a possible a cytokine-like molecule. First
identiﬁed by Said and Mutt in the late 1960s, VIP was
originally isolated as a vasodilator and hypotensive
peptide (5, 6). Later, its biochemistry was elucidated
and VIP’s signature features as a neuropeptide/neuro-
transmitter were consolidated, as a neuromodulator in
many organs and tissues, including heart, lung, thyroid
gland, kidney, immune system, urinary tract, and gen-
ital organs (7). The widespread distribution of VIP is
correlated with its involvement in a wide variety of
biological processes, from systemic vasodilatation, with
recently reported potential use as a new drug for
treatment of primary pulmonary hypertension (8), to
core clock functions, being the ﬁrst neuropeptide
reported to be important for maintaining stable circa-
dian clock function (9). It did not take long for these
insights to permeate the ﬁeld of immunology, from
which surprising new attributes for VIP have been
found over the last few years. VIP is rapidly transform-
ing into something more than a mere hormone/
neuropeptide, evolving scientiﬁcally from a neuropep-
tide to a novel agent for modifying immune function
and a possible a cytokine-like molecule. VIP research
has engaged many physiologists, molecular biologists,
biochemists, endocrinologists, and pharmacologists,
and VIP presents a paradigm to explore mutual inter-
actions between neural and neuroendocrine links in
health and disease.
During the last 5 years, the molecular machinery
accountable for the VIP-mediated anti-inﬂammatory
effects (10–12) has been unraveled. VIP is by far the
ﬁrst neuropeptide able to drive Th cell differentiation.
This is the framework for integrating the effects of VIP
on innate and adaptive immunity and for developing
alternative strategies against chronic inﬂammatory dis-
eases and autoimmune disorders (13). Anti-inﬂamma-
tory effects have recently been extended to those effects
through chemokine receptor function (14). Thus, VIP
may play an important role in problems related to
complexity and self-organization in a manner similar to
cytokines. In the next paragraphs, we highlight the
principal issues that have arisen in this area and offer a
ﬁnal reasoned outcome: that VIP should be considered
as a Th2 cytokine.
The key characteristics that a certain molecule must
possess in order to be considered a Th2 cytokine are to
1) be produced by Th2 cells in response to a speciﬁc
antigen stimulation; 2) stimulate and inhibit Th2 and
Th1 function/generation, respectively; 3) mediate au-
tocrine/paracrine actions involving the expression of
speciﬁc receptor in neighboring cells, and 4) act in a
pleiotropic and redundant way, inducing a Th2 biolog-
ical action (reducing the cellular-mediated inﬂamma-
tory response, favoring the humoral response). VIP
combines all of these.
VIP is produced by Th2 cells
It was recently that VIP was found to be released by
lymphoid innervation in close proximity to immune
cells and produced by most lymphocyte types (11).
However, VIP has been found to be speciﬁcally synthe-
sized and secreted by Th2 cells after speciﬁc antigen
stimulation (15). The physiological relevance of VIP
production by Th2 effectors might reside in the fact
that endogenous and exogenous VIP both promote
Th2-type responses in vivo, implicating VIP in the Th2
ampliﬁcation loop.
VIP promotes Th2-type immune responses
The adaptive immune response against a speciﬁc anti-
gen is initiated by the cellular contact between an
antigen-presenting cell (APC) and a naive T cell bear-
TABLE 1. General differences between cytokines and endocrine hormones
Property Cytokines Hormones
Sites of production Many Few
Cell targets Few Many
Biological role Immunity Homeostasis
Inﬂammation
Fighting infection
Tissue repair
Redundancy High Low
Pleiotropic action High Low
Circulatory levels Very low Moderate/high
Inﬂuence range Local: autocrine/paracrine Systemic: widespread
Inducers External insults Physiologic variation
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ing the appropriate T cell receptor (TCR). Stimulatory
(MHC-II/Ag on the APC, TCR on the T cell) and
costimulatory (B7.1/B7.2 and CD40 on the APC and
CD28 and CD40L on the T cell) interactions are both
required for activation of naive T cells. Upon activation,
antigen-speciﬁc T cells express high-afﬁnity IL-2 recep-
tors and proliferate in response to autocrine or para-
crine IL-2. After antigenic stimulation and prolifera-
tion, CD4 T cells differentiate into Th1 and Th2
effector cells, characterized by speciﬁc cytokine proﬁles
and functions. Th1 cells secrete cytokines (IL-2, IFN,
and TNF) critical for generation of a cellular immune
response, thereby activating macrophages, inducing
delayed-type hypersensitivity responses, and stimulating
IgG2a antibody production by B cells in mice. Th2 cells
produce IL-4, IL-5, and IL-10, which are critical for
IgG1 and IgE synthesis and immunity against helmin-
thic parasites; they increase of allergic reactions and
inhibit macrophage activation and antigen presenta-
tion, down-regulating the cellular immune responses
(Fig. 2). Determining factors for differentiation into
Th1 or Th2 effectors include the nature of the APCs,
the nature and amount of antigen, the genetic back-
ground of the host, and particularly the cytokine mi-
croenvironment. Recent studies clearly demonstrate
that VIP acts as an important endogenous T helper
differentiating factor, promoting Th2-type and inhibit-
ing Th1-type responses in vivo and in vitro. Indeed,
macrophages and dendritic cells (DC) treated in vitro
with VIP gain the ability to induce Th2-type cytokines
(IL-4, IL-5) and inhibit Th1-type cytokines (IFN, IL-2)
in antigen-primed CD4 T cells. In agreement with in
vitro results, in vivo administration of VIP in immu-
nized mice results in a decreased number in Th1 cells
and an increased number of Th2 cells (16, 17). In
another different approach, two experimental animal
models clearly show the Th2 bias mediated by VIP (18,
19). The research team led by Goetzl used genetically
modiﬁed mice to overcome the low potency of VIP
receptor antagonists. The autocrine/paracrine role of
VIP as a Th2 cytokine-like molecule is possible by fully
functional expression of VIP receptors in the immune
system. The ﬁrst reports of VIP receptors in the im-
mune system were claimed in human peripheral blood
lymphocytes in the early 1980s (20). Receptors for VIP
and the related molecule PACAP belong to group II of
the G-protein-coupled receptors. So far, three recep-
tors that display high afﬁnity for VIP and PACAP have
been cloned and, according to the established IUPHAR
nomenclature, are named VPAC1, VPAC2 (high afﬁnity
for both VIP and PACAP), and PAC1 (selective afﬁnity
for PACAP). The best-characterized effect after the
engagement of VPAC receptors is the accumulation of
intracellular cAMP and the activation of PKA through
stimulation of the  subunits of Gs proteins. Expression
of genes encoding VPAC receptors are relatively well
characterized in the immune system, although the
molecular mechanisms that drive their transcription
are poorly understood. VPAC2 expression on T cells is
induced only after TCR stimulation or exposure to
particular cytokines whereas VPAC1 mRNA is constitu-
tively expressed. Thus, Goetzl and co-workers engi-
neered a T cell-targeted mouse line in which VPAC2 is
constitutively expressed on CD4 T cells at levels
characteristic of those in normal cells after maximal
TCR stimulation (18) and a counterpart VPAC2
/
knockout mouse line (19). The two models showed
opposite immune phenotypes—the former toward a
Th2 proﬁle and the latter toward a Th1 proﬁle. Con-
sequently, VPAC2 null mice have increased cutaneous
delayed-type hypersensitivity and markedly decreased
cutaneous immediate-type hypersensitive. Therefore,
the major differences between effector T cell pheno-
types of these mouse models are clearly dependent on
T cell VIP receptors and cytokines and generally agree
as to opposite skewing of the Th1/Th2 cytokine ratio. A
deﬁnitive conﬁrmation of the role of endogenous,
Th2-derived VIP in maintaining the Th2 bias recently
came from studies by Voice et al., in which elimination
of VIP from TCR-stimulated T cells from VPAC2 trans-
genic mice with VIPase IgG resulted in a readjustment
of the Th1/Th2 balance, decreasing secretion of IL-4
and IL-10 and increasing the production of IFN (21).
Several nonexcluding mechanisms could contribute to
the Th2 bias by VIP. The spectrum of VIP effects
leading to Th2 cell predominance includes action at
the level of Th1/Th2 generation, either directly or
through actions on APCs and/or at the level of the
already generated effectors, by selectively promoting
Th2 proliferation, survival, or accumulation (Fig. 2).
Data from studies of VPAC2 transgenic mice high-
light the fact that endogenous VIP recognized by CD4
T cells is a key factor in the ﬁnal Th phenotype
outcome (21). Therefore, we should start thinking
about how to explain the apparently contradictory
results from a new standpoint in which VIP is regarded
as a cytokine. Thus, VIP could act at different opera-
tional levels. In vivo animal disease models can show us
how to determine whether VIP is or is not set as a
regulatory cytokine and at which operational level in a
given disease compared with a physiological scenario.
These data will then provide us with the insight needed
to deﬁne whether therapeutic application should be
effective or not.
VIP is an endogenous anti-inﬂammatory factor
Successful elimination of pathogens requires the initi-
ation and participation of innate and adaptive immu-
nity. However, once the pathogen is eliminated, cells
participating in innate and adaptive immunity must be
deactivated or eliminated in order to re-establish im-
mune homeostasis. Uncontrolled activation of the im-
mune system leads to serious consequences for the host
such as tissue destruction and organ failure, even
death. In addition to apoptosis of activated immune
cells, several endogenous agents such as anti-inﬂamma-
tory cytokines, lipid mediators, and glucocorticoids
down-regulate inﬂammatory processes. Recently, VIP
was added to the list of endogenous anti-inﬂammatory
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agents. This is a general prerequisite for a Th2 cyto-
kine. Thus, VIP has been used or suggested for the
development of therapies for several disorders (22),
but its role as a Th2 cytokine makes it an attractive asset
for studying inﬂammatory and/or Th1-type autoim-
mune diseases. The clinical implications of VIP re-
search include septic shock, rheumatoid arthritis,
Crohn’s disease, Parkinson’s disease (PD), and brain
trauma. Some of the mechanisms involved emphasize
the cytokine-related nature of VIP as striking parallel-
isms with typical Th2 cytokines such as IL-4, IL-10, or
IL-13 become apparent.
It is generally recognized that the severe pathological
consequences of the septic shock syndrome give rise to
a hyperactive and an out-of-balance network of endog-
enous proinﬂammatory cytokines including TNF, IL-
12, IL-6, and IFN (23). The overproduction of inﬂam-
matory cytokines generates systemic activation, which
affects vascular permeability and cardiac function, in-
duces metabolic changes that can lead to tissue necro-
sis, and eventually to multiple organ failure and death.
Since VIP inhibits the production of proinﬂammatory
macrophage-derived cytokines in vivo and in vitro, it
was expected to protect against endotoxemia. Indeed,
VIP administration protects against high lethal endo-
toxemia in a murine model for septic shock syndrome
(24). Endotoxemic animals suffer from generalized
intravascular coagulation with multiple organ failure as
evidenced by severe congestion, hemorrhage, hyper-
emia, ﬁbrin deposits, edema, thrombosis, and massive
accumulation of leukocytes in lungs and the intestinal
tract, as well as severe congestion of the medullar
sinusoids in the spleen, segmental ischemia of the
bowel with regions of hemorrhage or necrosis, and an
infracted cecum. In contrast, VIP-treated individuals
did not present any of the histopathological alterations
associated with septic shock such as disseminated intra-
vascular coagulation, leukocyte inﬁltration and inﬂam-
mation in various organs, mesenteric ischemia, and
acute tubular necrosis in the kidneys (24). VIP acts
presumably by down-regulating proinﬂammatory medi-
ators such as TNF, IFN, IL-6, IL-12, and NO and
up-regulating production of IL-10 (25). Furthermore,
the inhibitory effect of VIP on the production of
proinﬂammatory chemokines is crucial in its preventive
action on endotoxemia (26), because transmigration of
inﬂammatory cells to target inﬂamed organs is one of
the Initial events. It has recently been reported that VIP
inhibits cell responses to chemokines in monocytes and
CD4 T cells by trans-deactivating chemokine recep-
tors, a mechanism involving chemokine receptor phos-
phorylation (14). Other studies (27) have suggested
that the protective effect of VIP on septic shock syn-
drome is mediated through the regulation of serum
levels of hormones such as adrenaline and cortisol,
which control hemodynamic constants, important
events in the pathology of sepsis.
VIP has also emerged as an attractive candidate for
the treatment of arthritis. Two recent reports (13, 28)
using the animal model of collagen-induced arthritis
(CIA) have demonstrated that treatment of arthritic
mice with VIP decreases the frequency, delays the
onset, and reduces the severity of the disease. The
therapeutic effect of VIP on arthritis is associated with
a striking reduction of the two deleterious components
of the disease: the autoimmune and inﬂammatory
response. VIP reduces the titter of autoreactive anti-
collagen antibodies (particularly IgG2a antibodies) in
response to a reduction in the collagen-speciﬁc T cell
response, accompanied by a Th2 hallmark reduction in
IFN production and an increase in IL-4. There are
possible side effects to the chronic administration of
VIP, including gastrointestinal effects and generalized
immunosuppression, but such adverse effects were ob-
served short-term in the experimental CIA model.
Regarding its effect in joint inﬂammation, VIP strongly
reduces the inﬂammatory response during arthritis
development by down-regulating production of several
proinﬂammatory agents in the inﬂamed joints and
synovial cells, including TNF, IL-6, IL-1, iNOS, IL-12,
and IL-18, as well as various chemokines (RANTES,
MCP-1, MIP-1, MIP-1, MIP-2) reported to play a role
in inﬂammation and in the development of arthritic
responses (29). VIP levels are speciﬁcally increased in
serum and joints of arthritic mice during disease devel-
opment (30), demonstrating that endogenous neuro-
immune factors act as natural anti-arthritic agents
activated in response to autoimmune/inﬂammatory
conditions to counterbalance the effects of inﬂamma-
tory mediators.
Although its etiology is unknown, Crohn’s disease
has been shown to be marked by an exaggerated
gut-associated, lymphoid tissue-developed immune re-
sponse, giving rise to a prolonged severe inﬂamed
intestinal mucosa characterized by uncontrolled pro-
duction of proinﬂammatory cytokines and by oligo-
clonal expansion and activation of CD4 T cells, spe-
ciﬁcally associated with a Th1 response (31). In a recent
report, Abad and co-workers (32) used the established
murine model of Crohn’s disease induced by intrarec-
tal administration of trinitrobenzene sulfonic acid
(TNBS) to demonstrate that treatment with VIP re-
duced the clinical and histopathologic severity of
TNBS-induced colitis, abrogating body weight loss,
diarrhea, and intestinal inﬂammation. The therapeutic
effects of VIP occurred in all phases of the disease
(early, acute, and chronic). In the early acute phase of
bowel inﬂammation there is an overlapping of innate
and adaptive immune responses, with multiple media-
tors involved, such as chemokines and cytokines. VIP
signiﬁcantly reduced the inﬂammatory response by
down-regulating the production of different proinﬂam-
matory mediators involved in local and systemic dam-
age, such as TNF, IL-1, IL-6, IL-12, MIP-1, MCP-1,
MIP-2, and KC. This broad spectrum of action is related
to a decrease in colitis-associated inﬂammation and the
inﬁltration of neutrophils, macrophages, and CD4 T
cells in the lamina propria. Treatment with VIP par-
tially prevented TNBS-induced generation of CD4 T
cells and of Th1 responses. From a therapeutic point of
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Figure 2. Effects of VIP on CD4 T cell activation and differentiation. The same Th precursor (Thp) cell can differentiate into
Th0, Th1, or Th2 cells depending primarily on the cytokine microenvironment provided by DC and other antigen-presenting
cells (APCs): IL-12 induces Th1 cells, IL-4 promotes Th2 cells, whereas Th0 cells differentiate under neutral conditions with
optional IL-2. In addition, VIP released from antigen (Ag) -stimulated Th2 cells drives Th differentiation/generation acting on
CD4 T cells and APCs. a) Action on APCs: differentiation into Th2 effectors depends on the expression of the membrane-bound
costimulating factors B7 to a much larger degree than differentiation into Th1 effectors. VIP induces B7.2 expression on resting
macrophages (M) and DCs and promotes Th2-type responses. b) Action on Th1/Th2 effectors: the majority of Th1 and Th2
effectors are eliminated through Fas/FasL-mediated apoptosis (AICD, antigen-induced cell death), with a small number
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view, it is important to point out that VIP reduced
disease severity even when given after the onset of the
disease. Therefore, VIP could represent a possible
multistep therapeutic agent for Crohn’s disease.
In several neurodegenerative disorders, including
PD, Alzheimer’s disease, multiple sclerosis, and AIDS
dementia, neuronal cell death occurs subsequent to
inﬂammatory responses, mediated at least partially by
activated microglia (33). Proinﬂammatory cytokines
are known to participate in mitochondrial impairment
and oxidative stress; therefore, an inﬂammatory re-
sponse may serve as an integral feature of the mecha-
nistic underpinning related to PD pathogenesis. Be-
cause VIP has been shown to act as a “microglia-
deactivating factor” under inﬂammatory conditions
and to prevent inﬂammation-induced neurodegenera-
tion (34), this peptide emerges as a plausible candidate
for neuroprotection under inﬂammatory conditions,
including PD. VIP prevents MPTP-induced activation of
microglia and expression of the cytotoxic mediators
iNOS, IL-1, and TNF, and NADPH-oxidase. These
ﬁndings indicate important future directions, includ-
ing a possible therapeutic role of VIP in brain disorders
such as PD itself or multiple sclerosis, Alzheimer’s
diseases, and AIDS dementia, where the inﬂammatory
response plays a major role. Recently, VIP cytokine-like
behavior has demonstrated a potential therapeutic
effect of VIP in brain traumas, where an increased level
of proinﬂammatory cytokines is a normal and early
feature of the CNS response to trauma (35); it remains
controversial, however, whether inﬂammation in the
injured CNS serves a beneﬁcial or detrimental purpose
(36). In a model of adult mice stab wound brain trauma
in the periventricular area, VIP has been shown to
signiﬁcantly reduce all pathological hallmarks that fol-
low brain injury: dramatic neurodegeneration, recruit-
ment of mononuclear phagocytes, microglia activation,
and increased production of TNF and IL-1 (37). A
direct link between VIP and the response to neuronal
insults has been reported. In this case, VIP provides
neuronal defense by inducing the synthesis and secre-
tion of neuroprotective proteins from astrocytes (38).
VIP modulates the function of inﬂammatory cells
through speciﬁc G-protein-coupled receptors (Fig. 3);
extensive literature has been published on VIP recep-
tors (39). We shall focus here on some of the questions
that remain to be addressed as well as some of the
hypotheses currently being scrutinized in our labora-
tory. Recent advances in molecular and cell biology
enabling the cloning, expression, and mutagenesis of
VIP receptors have prompted an explosion of knowl-
edge in the ﬁeld, facilitating the discovery of new
classes of regulatory proteins and providing a basis and
means for manipulating receptor function. Combined
functional information from early stages in VIP recep-
tor research showed several common features such as a
strong coupling to the activation of adenylyl cyclase and
the ability to interact in a species-speciﬁc manner with
related peptides such as secretin, helodermin, growth
hormone-releasing factor, or peptide histidine iso-
leucineamide. Some of these peptides were encoded
within the VIP precursor polypeptide mRNA as addi-
tional biologically active peptides acting most likely
through VIP receptors (as mentioned above; VPAC1,
VPAC2, and PAC1) instead of different and speciﬁc sets
of receptors. An open question still to be determined is
to what extent these peptides have immunomodulatory
capabilities and whether this degeneracy could regulate
the effects mediated by the VIP itself. There are no data
on possible differential post-translational processing
under different immune conditions to account for
putative ﬁne-tuning mechanisms of counter regulation
exploiting the “less-than-discriminate” nature of ligand-
receptor interactions. From a pharmacological point of
view, these natural peptides structurally related to VIP
have a limited utility. An important point in establish-
ing the role of VPAC receptors was the development
during the past few years of selective agonists and
antagonists. Sequence alignment of PACAP, VIP, [K15,
R16, L27]VIP(1-7)/GRF(8-27), Ro 25-1553, and Ro 25-
1392 was recently analyzed to identify VPAC2 selective
determinants by saturation recombinant mutagenesis,
leading to the production of a highly selective and
potent VPAC2 agonist as a recombinant peptide (40).
The strategy followed by the above-cited authors over-
came important technical issues such as the absence of
exogenous amino acids without losing stability and
analysis of a large number of peptides and provides a
feasible method of industrial manufacture. It has re-
cently been shown that immunological tolerance to VIP
can be broken (41); thus, further regulation of VIP by
autoantibodies is undetermined. The possible presence
of autoreactive T clones against VIP could lead to a new
ways of immunointervention by T cell vaccination.
Localization of VPAC receptors and its consequences
on immunocompetent cells would lead to new paradigms
of VIP’s mechanism of action. We are only beginning to
unravel the functional implication that G-protein-coupled
receptor homo- and heterodimerization represent. Fu-
ture research in VPAC receptor dimerization could be
critical for novel drug design in the context of the
immune system. After binding to their speciﬁc receptors,
chemokines, as occurs for other GPCRs, induce receptor
dimerization. Bioinformatic analysis shows that some dy-
surviving as memory T cells. VIP promotes the preferential survival of Th2 vs. Th1 effectors. c) Action on activated macrophages:
VIP inhibits IL-12 production by activated macrophages, reducing differentiation into Th1 effectors. d) Action on Th1/Th2-
speciﬁc chemokines: IP10 and MDC are DC/macrophage-derived chemokines that speciﬁcally attract Th1 and Th2 cells,
respectively. VIP inhibits and stimulates IP-10 and MDC production, respectively, and favors Th2 vs. Th1 chemoattraction to the
antigen presentation site. e) The possibility exists (indicated by a question mark) that VIPs act directly on CD4 T cells and bias
Th1/Th2 differentiation in favor of Th2 by promoting the expression of Th2 transcription factors (c-Maf, JunB, GATA-3) and
inhibiting the expression of T-bet (the Th1 master transcription factor).
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namic interactions between VPAC receptors and chemo-
kine receptors are possible.
CONCLUSIONS
Could VIP be considered a type 2 cytokine? The term
“cytokine” deﬁnes a protein secreted by leukocytes
(and other cell types) in response to tissue injury or
repair, acting predominantly in a local, paracrine, or
autocrine manner, with pleiotropic actions, including
effects on immune cells and modulation of the inﬂam-
matory response. If, in addition, such a protein is
produced by Th2 cells, it affects the Th1/Th2 balance,
enhancing Th2 and reducing Th1 generation/func-
tion, resulting in a generalized anti-inﬂammatory, anti-
helminthic, and atopic function, it is then included in
Figure 3. VPAC receptors on immune system couple to 1) stimulation of adenylyl cyclase triggering a protein kinase A
(PKA)-cAMP transduction pathway, and 2) activation of phospholipase C (PLC) and phospholipase D (PLD). VPAC receptors
induce responses by activating transduction systems that involve different G-proteins, with G as the best characterized in
different tissues and cell lines expressing recombinant receptors. Other G-proteins that have been shown to be coupled to VPAC
receptors belong to Gi/Go and Gq families (42, 43). Other VPAC partners different from G-proteins have been reported such
as the small G-protein ADP-ribosylation factor (ARF) or receptor activity-modifying proteins (RAMP), resulting in alterations of
receptor phenotype or pharmacological proﬁle (44, 45). These are not yet documented on immunocompetent cells. New
binding partners are being investigated by us as regulators of G-protein signaling (RGS). RGS proteins are important acting as
tightly regulated integrators of G-protein signaling and as scaffolds to assemble signaling complexes. PDZ motif-containing
proteins are also scaffold proteins with regulatory functions. VPAC1 and probably VPAC2 contain a typical binding site for PDZ
domains. The physiological signiﬁcance of PDZ-VPAC receptor interaction on immunocompetent cells is an open question. It
is interesting to hypothesize on the physical compartmentalization of VPAC receptors and the consequences in signal
transduction. Lipid rafts function in the initiation of signaling in a variety of immune cells and in the control of signaling by
coreceptors during development and differentiation and of infection. In this sense, lipid raft localization of VPAC receptors is
under current scrutiny.
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the group of type 2 cytokines. The ﬁndings shown here
indicate that VIP shares these characteristics.
It is clear that VIP is pleiotropic to an extreme.
Further research in our functional genomics era will
address how many genes VIP regulates at a molecular
level. These genes will probably be more or less pleio-
tropic themselves. Therefore, a single molecule like VIP
is pleiotropic in a well-known cytokine manner at the
most basic causal level. Moreover, the functional over-
lap between VIP and different immune-related mole-
cules presents another well-known cytokine character-
istic, that of redundancy. VIP and other Th2 cytokines
will only partially overlap in their effects; each molecule
produces effects that others do not. This degenerate
redundancy (partially overlapping pleiotropisms) is a
hallmark of cytokines.
In any case, whether VIP is considered a neuropep-
tide or a cytokine, it is evident it plays a key role in the
communication between the nervous and immune sys-
tems:
• as a neuropeptide produced by neurons directly
regulating nervous system functions;
• as a neuropeptide released by nerve endings in
the lymphoid organs regulating immune func-
tions;
• as a cytokine produced by T cells that regulates
the immune system functions in an autocrine/
paracrine way;
• as a cytokine released from T cells that controls
nervous system.
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